A practical reference on somatotroph: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
== Data management == The FDA has collected a large amount of data through the decades. The OpenFDA project was created to enable easy access of the data for the public and was officially launched in June 2014.
Distinguished for her research on the application of mass spectrometry to problems in chemical biology. She has used mass spectrometry to define the folding and binding of interacting proteins in large complexes. Most importantly, she has established that macromolecular complexes such as GroEL, ribosomes, and intact virus capsids can be generated in the gas phase and their electrospray mass spectra recorded. This work has demonstrated the power of mass spectrometry in studying very large complexes and allowed her to define changes in their conformation and the manner of their assembly. She was elected a Fellow of the Academy of Medical Sciences in 2009. In 2010, Robinson received the Davy Medal "for her ground-breaking and novel use of mass spectrometry for the characterisation of large protein complexes". In 2011, she was given the Interdisciplinary Prize by the Royal Society of Chemistry for "development of a new area of research, gas-phase structural biology, using highly refined mass spectrometry techniques", the Aston Medal, and the FEBS/EMBO Women in Science Award. She was appointed Dame Commander of the Order of the British Empire (DBE) in the 2013 New Year Honours for services to science and industry. She received the Thomson Medal Award in 2014.
=== Mechanism of action === Fremanezumab is a fully humanized monoclonal antibody directed against calcitonin gene-related peptides (CGRP) alpha and beta. It potently and selectively binds to CGRPs, which prevents binding to receptors.
Sources: en.wikipedia.org
Only two of the Russian frigates provided important services in the Caribbean in defense of the island of Cuba, although they only made the one-way trip, they got lost, sunk when they arrived in Havana.
After independence in 1947, Jinnah, the president of the Muslim League, became Pakistan's first governor-general and the first President-Speaker of the Parliament, but he died of tuberculosis on 11 September 1948. Meanwhile, Pakistan's founding fathers agreed to appoint Liaquat Ali Khan, the secretary-general of the party, the nation's first prime minister. From 1947 to 1956, Pakistan was a monarchy within the Commonwealth of Nations, and had two monarchs before it became a republic. The creation of Pakistan was never fully accepted by many British leaders, including Lord Mountbatten. Mountbatten expressed his lack of support and faith in the Muslim League's idea of Pakistan. Jinnah refused Mountbatten's offer to serve as Governor-General of Pakistan. When Mountbatten was asked by Collins and Lapierre if he would have sabotaged Pakistan had he known that Jinnah was dying of tuberculosis, he replied 'most probably'.
Azalides are a class of macrolide antibiotics that were originally manufactured in response to the poor acid stability exhibited by original macrolides such as erythromycin. Examples of azalides include azithromycin, which is used in humans, while tulathromycin and gamithromycin are used in veterinary medicine. Following the clinical overuse of macrolides and azalides, ketolides have been developed to combat surfacing macrolide-azalide resistance among streptococci species. Azalides have several advantages over erythromycin such as more potent gram negative antimicrobial activity, acid stability, and side effect tolerability. Although there are few drug interactions with azithromycin, it weakly inhibits the CYP3A4 enzyme.
=== Variation === The formyl group is not strictly required for initiation. Bacteria with their formyltransferase knocked out, which prevents Met-tRNAfMet (i.e. methionine loaded onto tRNAfMet) from turning into fMet-tRNAfMet, can have varying degrees of residual ability to start protein synthesis. E. coli, S. pneumoniae and B. subtilis show almost no remaining translation ability, while P. aeruginosa, S. aureus, H. influenzae, and possibly S. faecalis still churn out plenty of protein. In P. aeruginosa, this ability is facilitated by bacterial initiation factor 2, which can carry both Met-tRNAfMet and fMet-tRNAfMet to the ribosome.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.